Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cetrelimab

Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Janssen Research & Development, LLC

Phase 1 Most advanced trial
JNJ Developer
1 Registered trials

What is Cetrelimab?

Cetrelimab is a monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2. By preventing PD-1-mediated inhibitory signaling, it promotes T-cell activation and T-cell responses against tumor cells. It is being studied in neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JNJ-63723283
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1)
Mechanism
Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1 signaling, T-cell activation
Therapy area
Oncology
Developer
Janssen Research & Development, LLC (JNJ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
LYK98WP91F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07525141 Phase 1 Neoplasms Recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neoplasms

Other drugs acting on PDCD1

More from Janssen Research & Development, LLC

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Cetrelimab

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.